Business Wire

GXP-Storage ® Expands Global Reach with New U.K. Site

8.9.2025 14:00:00 CEST | Business Wire | Press Release

Share

GXP-Storage®, the premier provider of regulated life sciences material storage solutions, today announced its strategic expansion into the U.K.'s Golden Triangle Region. This new site directly addresses the growing demand from multinational clients seeking seamless, compliant storage solutions and access to industry-leading technology across continents. The company now serves over 150 life science and healthcare clients in North America and Europe at its fully operational sites.

The new U.K. site leverages GXP-Storage's cutting-edge GXP-Guardian® platform to ensure standardized operations and seamless material visibility across continents. This expansion directly responds to increasing client demand for scalable storage solutions while maintaining local expertise and consistent responsive service delivery, making GXP-Storage the trusted long-term partner for life sciences and healthcare organizations.

"This expansion delivers three critical benefits to our clients: consolidated compliance oversight, real-time material visibility, and cost optimization through consolidation," said Jeff Johnson, CEO of GXP-Storage. "By expanding our service delivery footprint in the U.K.'s Golden Triangle Region, we're ensuring our clients maintain the same regulatory-compliant material storage solutions and access to technology in the transatlantic ecosystem that serves as international consolidation points for life science and healthcare organizations."

Strategic Site Supports Growth in the EMEA Region

The U.K.'s Golden Triangle Region, encompassing London, Oxford, and Cambridge, represents one of the world's most concentrated life sciences and healthcare ecosystems. In 2024, life sciences businesses drove nearly 60% of office and lab leasing activity in Oxfordshire and 70% in Cambridge, according to Carter Jonas’s Spring 2025 Life Sciences Research Report. The momentum continued into 2025, with U.K. life science companies securing a record £1.25 billion in venture capital funding during Q1 alone, the highest quarterly total on record. With 4.0 million square feet of additional lab space under construction for delivery by 2027, the region contributes over £13 billion annually to the U.K. economy.

This strategic location provides direct access to leading pharmaceutical companies, innovative biotechs, world-class universities, and healthcare service providers throughout Europe. Clients can ship materials to and from these sites to most global life sciences and healthcare locations within 24 hours.

Addressing Critical Global Operational Challenges

Multinational life sciences and healthcare companies struggle with materials scattered across fragmented locations worldwide, resulting in growing costs, limited visibility, and compliance gaps. Our U.K. storage site directly addresses these challenges by providing secure, environmentally controlled storage capacity and related logistics expertise. This unified approach delivers measurable financial benefits, strengthened compliance oversight, enhanced visibility, and simplified management, all through one strategic partner and one technology platform.

Ensuring Seamless Global Operations via AI-Enabled Technology Platform

GXP-Guardian, the industry's leading material management technology platform providing complete visibility across multiple sites, anchors this global expansion. This regulatory-compliant, validated system enables organizations to monitor materials across the transatlantic ecosystem through one secure interface, maintaining a comprehensive electronic chain of custody and audit trail, facilitating audit-ready compliance with supporting documentation regardless of geographic location.

"Global operations demand more than consolidated storage; they require operational efficiency and consistent quality standards," Johnson continued. "Our investment in standardized operations powered by GXP-Guardian means our clients’ effort is reduced to manage the lifecycle of their regulated material cost-effectively with consistent quality."

Supporting Innovation Across Multiple Continents

GXP-Storage sites provide scalable storage capacity in controlled ambient to cryogenic environments monitored 24/7 with redundant systems and emergency response teams to ensure secure pre-clinical and clinical research, healthcare research, and manufacturing material preservation. All sites support a consistent quality management system, site-specific certifications, and responsive customer service that define the GXP-Storage standard.

Client onboarding leverages GXP-Storage's proven implementation methodology, ensuring smooth transitions for organizations expanding into U.K. operations or consolidating fragmented material and related data. The unified GXP-Guardian platform provides our growing list of clients with real-time access, visibility, and control. With both sites now operational, GXP-Storage offers a global standard.

About GXP-Storage

GXP-Storage® is the strategic partner in regulated material management for life sciences and healthcare organizations navigating complex compliance requirements. With advanced facilities, deep regulatory expertise, and the proprietary GXP-Guardian® platform, GXP-Storage provides real-time visibility and control across all storage environments, helping life sciences and healthcare organizations focus on advancing discovery through quality of care. The company's integrated lifecycle management approach eliminates the complexity of coordinating multiple vendors while ensuring materials remain secure, compliant, and accessible from research through commercialization.

To learn more, visit gxp-storage.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250908027553/en/

Contacts

Media Contact
FGS Global
WhistlerCapital@fgsglobal.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye